Get the Stockscreener App
9.73
7.28%
0.66
After Hours:
9.73
Eikon Therapeutics Inc stock is traded at $9.73, with a volume of 265.70K.
It is up +7.28% in the last 24 hours and down -26.57% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$9.07
Open:
$9.14
24h Volume:
265.70K
Relative Volume:
0.78
Market Cap:
$526.77M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.1714
EPS:
-4.481
Net Cash Flow:
-
1W Performance:
+16.39%
1M Performance:
-26.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.00
$9.86
1-Week Range:
$8.01
$9.89
52-Week Range:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Name
Eikon Therapeutics Inc
Sector
Industry
Phone
341-777-0566
Address
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
9.73 | 505.11M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
Soros opened a brand new EIKN position — moomoo's New tab ca...moomoo Community - Moomoo
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating (NASDAQ:EIKN) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Eikon Therapeutics Appoints Ma. Fatima Francisco to Board - The Globe and Mail
New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics discloses new USP1 inhibitors - BioWorld News
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026 - marketscreener.com
Eikon Therapeutics appoints Francisco to board of directors By Investing.com - Investing.com Nigeria
Eikon Therapeutics appoints Francisco to board of directors - Investing.com India
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors - Yahoo Finance
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.8, Implies 158% Upside - TradingView
BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Cuts Target Price to $32 - Moomoo
Cantor Fitzgerald reiterates Overweight on Eikon stock By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com UK
Eikon Therapeutics 2026 Pipeline Update: Promising Clinical Results for TLR7/8, PARP1, and WRN Inhibitors in Oncology - Minichart
Eikon Therapeutics (EIKN) highlights EIK1001 NSCLC and EIK1003 solid tumor data at ASCO 2026 - Stock Titan
J.P. Morgan Maintains Eikon Therapeutics(EIKN.US) With Buy Rating - Moomoo
Eikon Therapeutics, Inc.Common Stock (Nasdaq:EIKN) Stock Quote - The Chronicle-Journal
Eikon Therapeutics reports promising Phase 2 NSCLC and Phase 1/2 solid tumor trial data at ASCO 2026 - Pluang
Eikon Therapeutics Completes Enrollment for Phase 2 TeLuRide-005 Trial of EIK1001 in Stage 4 NSCLC and Reports Promising Clinical Data for EIK1003 - Quiver Quantitative
Experimental Eikon drugs show responses in advanced lung and ovarian cancer - Stock Titan
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology - The Manila Times
Eikon to present clinical data on three cancer programs at ASCO - Investing.com UK
Eikon Therapeutics to present six abstracts on cancer drug trials at 2026 ASCO meeting - Pluang
Eikon Therapeutics Announces Presentation of Advanced Clinical Data at 2026 ASCO Annual Meeting - Quiver Quantitative
Eikon Therapeutics Announces Availability of Six Abstracts - GlobeNewswire
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Innovation Endeavors reports 3.37M shares in Eikon Therapeutics (EIKN) - Stock Titan
BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $34 - Moomoo
EIKN Should I Buy - Intellectia AI
Roger Perlmutter holds 2.89M shares of Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan
Wedbush Maintains Eikon Therapeutics(EIKN.US) With Sell Rating, Cuts Target Price to $5 - Moomoo
Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating - marketscreener.com
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Sahm
Eikon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IPO cash lifts Eikon Therapeutics (NASDAQ: EIKN) to $596M - Stock Titan
Eikon Therapeutics (Nasdaq: EIKN) details Q1 loss and ASCO 2026 data plans - Stock Titan
Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Moomoo
FMR LLC holds 3.84M EIKON Therapeutics shares (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Eikon Therapeutics Inc Stock (EIKN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eikon Therapeutics Inc Stock (EIKN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Capital Management IV | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
55,555 |
999,990 |
1,318,983 |
| FRAZIER KENNETH C | Director |
Feb 04 '26 |
Buy |
18.00 |
111,111 |
1,999,998 |
111,111 |
| Wolfe Josh | Director |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
| Lux Venture Partners V, LLC | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):